Related Experiment Videos
Chemotherapy for advanced disease. How to raise enthusiasm
1European Organization for Research and Treatment of Cancer (EORTC), London, UK.
Chest
|May 1, 1996
Summary
Newer chemotherapy drugs offer hope for non-small cell lung cancer (NSCLC) patients. However, organizing large clinical trials is challenging due to physician attitudes, costs, and poor cooperation, necessitating improved communication strategies.
Area of Science:
- Oncology
- Clinical Trials
- Medical Communication
Background:
- Recent advancements in chemotherapy, including cisplatin, vindesine, vinorelbine tartrate (Navelbine), taxoids, and gemcitabine, have improved treatment prospects for non-small cell lung cancer (NSCLC).
- Despite therapeutic progress, conducting adequately powered clinical trials to demonstrate significant differences in NSCLC treatment outcomes remains a substantial challenge.
Purpose of the Study:
- To identify barriers to organizing large-scale clinical trials for non-small cell lung cancer.
- To propose strategies for enhancing communication and cooperation among stakeholders to facilitate trial organization and improve NSCLC treatment research.
Main Methods:
- The study reviews challenges in NSCLC clinical trial organization.
- It emphasizes the need for enhanced communication and collaboration among healthcare professionals, research organizations, and patients.
Main Results:
- Key barriers include negative physician attitudes, high patient enrollment costs, and fragmented research efforts.
- Effective communication strategies are crucial for overcoming these obstacles.
Conclusions:
- Improved communication involving oncologists, lung physicians, surgeons, and patients is essential for successful NSCLC clinical trials.
- Strategies include targeted journal publications, inter-organizational collaboration, integrated information networks, and media engagement to foster a more cooperative research environment.